Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England.

The first PI3K inhibitor to reach the US market for a breast cancer indication was Novartis' Piqray/Vijoice (alpelisib), cleared in 2019 as a second-line therapy alongside fulvestrant for patients ...